5-(4-methoxyphenyl)-2-phenyloxazole-4-carboxylic acid | 1019114-71-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(4-methoxyphenyl)-2-phenyloxazole-4-carboxylic acid
• 英文别名: 5-(4-methoxyphenyl)-2-phenyl-1,3-oxazole-4-carboxylic acid
• CAS: 1019114-71-6
• 化学式: C₁₇H₁₃NO₄
• 分子量: 295.295
• InChiKey: UPZYHHPLISGNJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  72.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(4-methoxyphenyl)-2-phenyloxazole-4-carboxylic acid 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 70.0h， 以70%的产率得到5-(4-methoxyphenyl)-2-phenyl-1,3-oxazole
  参考文献：
  名称：

  铜催化的功能化酰胺的分子内环化反应合成2-苯基-4,5-取代的恶唑

  摘要：

  已经报道了2-苯基-4，5-取代的恶唑的有效两步合成，其中涉及高度功能化的新型β-（甲硫基）烯酰胺的分子内铜催化的环化作为关键步骤。这些酰胺是通过新合成的4-[（（甲硫基）杂（芳基）亚甲基] -2-苯基-5-恶唑烷酮前体的亲核开环反应，通过醇盐，胺，氨基酸酯和芳基/烷基格氏试剂进行亲核开环而获得的。在产物恶唑的4-位引入酯，N-取代的羧酰胺或酰基官能团。还描述了通过相应的2,5-二芳基恶唑-4-羧酸酯的两步水解-脱羧反应合成两种天然存在的2,5-二芳基恶唑，即texamine和uguenenazole。相似地，通过DAST / DBU介导的环脱水-脱卤化氢序列，将三种丝氨酸衍生的oxazole-4-carboxamides精制为新型三取代的4,2'-bisoxazoles。本协议是对我们先前报道的碳酸银诱导的β-双（甲硫基）烯酰胺成2-苯基-5-（甲硫基）-4-取代的恶唑环化的补充和改进。

  DOI：

  10.1021/jo3021192
• 作为产物：
  描述：

  4-(4-methoxybenzylidene)-2-phenyl-5(4H)-oxazolone 在 溴 、 碳酸氢钠 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 1.0h， 生成 5-(4-methoxyphenyl)-2-phenyloxazole-4-carboxylic acid
  参考文献：
  名称：

  Efficient Synthetic Approach to Fluorescent Oxazole-4-carboxylate Derivatives

  摘要：

  In our attempt to synthesize a halogenated analog of green fluorescent protein (GFP) chromophore, we discovered a simple and efficient synthetic strategy to the derivatives of oxazole-4-carboxylic acid substituted at positions 2 and 5. The method allows for introduction of different aryl substituents at the position 5, aryl or alkyl substituents at position 2 of oxazole, and gives access not only to free carboxyl at position 4, but also to a range of its amide derivatives. The advantages of the synthetic strategy presented are availability of precursors, good yields, and avoiding palladium coupling and metalation procedures. The synthesized compounds fluoresce in visible region with quantum yields up to 0.82. We believe that 5-aryl-4-carboxyoxazole is a promising core for creation of new fluorescent dyes. Supplemental materials are available for this article. Go to the publisher's online edition of Synthetic Communications (R) to view the free supplemental file.

  DOI：

  10.1080/00397911.2012.706350

文献信息

• Oxazole tyrosine kinase inhibitors
  申请人：Reader John Charles

  公开号：US08378095B2

  公开（公告）日：2013-02-19

  The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R1; Ar2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R2; and R1 and R2 are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.

  本发明提供了一种化合物，其为公式（1）的酰胺或其盐、溶剂合物、N-氧化物或互变异构体；其中：a为0或1；b为0或1：前提是a和b的和为0或1；T为O或NH；Ar1为单环或双环的5-至10-成员芳基或杂芳基，包含最多4个从O、N和S中选择的杂原子，并且可以被一个或多个取代基R1取代；Ar2为单环或双环的5-至10-成员芳基或杂芳基，包含最多4个从O、N和S中选择的杂原子，并且可以被一个或多个取代基R2取代；其中R1和R2如权利要求所定义。这些化合物是激酶抑制剂，特别是FLT3、FLT4和Aurora激酶的抑制剂。
• OXAZOLE TYROSINE KINASE INHIBITORS
  申请人：Sareum Limited

  公开号：US20130102592A1

  公开（公告）日：2013-04-25

  The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar 1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted en by one or more substituents R 1 ; Ar 2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R 2 ; and R 1 and R 2 are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.

  本发明提供了一种化合物，其为公式（1）的酰胺或其盐、溶剂合物、N-氧化物或互变异构体；其中：a为0或1；b为0或1：前提是a和b的和为0或1；T为O或NH；Ar1为含有最多4个来自O、N和S的杂原子的单环或双环5-至10-成员芳基或杂芳基基团，并且可以被一个或多个取代基R1取代；Ar2为含有最多4个来自O、N和S的杂原子的单环或双环5-至10-成员芳基或杂芳基基团，并且可以被一个或多个取代基R2取代；R1和R2如权利要求所定义。该化合物是激酶抑制剂，特别是FLT3、FLT4和Aurora激酶的抑制剂。
• WO2008/139161
  申请人：——

  公开号：——

  公开（公告）日：——
• Solution versus Fluorous versus Solid-Phase Synthesis of 2,5-Disubstituted 1,3-Azoles. Preliminary Antibacterial Activity Studies
  作者：Juan F. Sanz-Cervera、Raül Blasco、Julio Piera、Michael Cynamon、Ignacio Ibáñez、Marcelo Murguía、Santos Fustero

  DOI：10.1021/jo9016265

  日期：2009.12.4

  A small library of compounds with an oxa(thia)zole scaffold and structural diversity in both positions 2 and 5 has been synthesized. Double acylation of a protected glycine affords intermediate alpha-amido-beta-ketoesters, which in turn can be dehydrated to afford 1,3-oxazoles or reacted with Lawesson's reagent to furnish 1,3-thiazoles. This procedure was designed with its adaptation to fluorous techniques in mind. Thus, when a protected glycine With a fluorous tag in the ester moiety IS used as a starting material, the synthesis can be easily completed Without column chromatography purification of intermediate compounds with good to excellent yields, thus affording a Suitable entry to the preparation of small libraries of these bioactive compounds. The prepared oxa(thia)zoles were assayed for their antibacterial activity, and several of them were active against Staphylococcus aureus.
• US20140275041A1
  申请人：——

  公开号：——

  公开（公告）日：——